A Study of the Application of HAIC in Advanced HCC Previously Treated With ICIs and Antiangiogenic Agents
Status:
Recruiting
Trial end date:
2026-10-18
Target enrollment:
Participant gender:
Summary
Immune checkpoint inhibitors (ICIs) plus antiangiogenic agents can achieve better efficacy
than sorafenib in the treatment of hepatocellular carcinoma (HCC) within a certain period of
time, but more than half of the patients are still insensitive to the treatment. There is no
evidence-based basis for second-line treatment after the progression of the disease.In view
of the effectiveness of Hepatic arterial infusion (HAIC) in the first-line treatment of HCC
in the Chinese population, this study intends to launch a prospective intervention study to
explore the efficacy and safety of HAIC treatment in patients with advanced HCC after the
failure of ICIs and antiangiogenic agents combination therapy, and to provide high-level
evidence for optimizing the second-line treatment of advanced HCC in the future.